Demplatin Pegraglumer

Summary

Demplatin Pegraglumer (CHEMBL4298052) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including pancreatic neoplasm and head and neck squamous cell carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298052
Name	Demplatin Pegraglumer
Type	Small molecule
Max phase	3

Also known as: Demplatin pegraglumer, Demplatine pegraglumere, Demplatino pegraglumero, Nc-6004, NC-6004, NC-6004 NANOPLATIN, DEMPLATIN PEGRAGLUMER

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pancreatic neoplasm	3	MONDO:0021040	EFO:0003860
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
squamous cell carcinoma	2	MONDO:0005096	EFO:0000707
neoplasm	1	MONDO:0005070	EFO:0000616
upper aerodigestive tract neoplasm	1	MONDO:0005398	EFO:0004284

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02043288	PHASE3	COMPLETED	Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
NCT02240238	PHASE1/PHASE2	COMPLETED	Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
NCT03109158	PHASE1/PHASE2	COMPLETED	NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT03771820	PHASE2	UNKNOWN	Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen
NCT02817113	PHASE1	TERMINATED	Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).